Table 4.
Efficacy Results of Nivolumab as Second-Line Treatment of Metastatic Squamous NSCLC.
| Efficacy | Nivolumab (n = 135) | Docetaxel (n = 137) |
|---|---|---|
| Prespecified Interim Analysis | ||
| Events (%) | 86 (64%) | 113 (82%) |
| Median survival in months (95% CI) | 9.2 (7.3, 13.3) | 6.0 (5.1, 7.3) |
| p-Value a | 0.00025 | |
| Hazard ratio (95% CI) b | 0.59 (0.44, 0.79) | |
a p-Value is derived from a log-rank test stratified by region and prior to paclitaxel use; the corresponding O’Brien-Fleming efficacy boundary significance level is 0.0315; b Derived from a stratified proportional hazards model.